| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.97 | 17.9% | 13.9% |
| Total Income | 1.97 | 17.9% | 13.9% |
| Expenditure | 5.14 | 26.3% | 11.0% |
| PBT | -4.83 | 6.4% | 61.5% |
| Net Profit | -4.83 | 6.4% | 61.5% |
| OPM | — | ||
| NPM | — | ||
| EPS | -26.64 | 1116.4% | 56.3% |
Nuwellis Reports Q2 2026 Financial Results with Double Digit Revenue Growth and Expanded Gross Margin
14 Aug 2026 · 14 Aug, 2:17 am
Summary
Nuwellis, Inc. reported a 14% increase in net sales to $2.0 million for the second quarter of 2026, driven by higher U.S. circuit and console sales. Gross margin saw a significant improvement, rising to 76% from 56% in the prior-year quarter due to better pricing, product mix, and a transition to contract manufacturing. The company also highlighted its strengthened cash position following recent financing activities and progress on strategic priorities, including advancing its Aquadex label expansion.
Key Highlights
- 1
Nuwellis reported net sales of $2.0 million for the second quarter of 2026, representing a 14% increase compared to the prior-year period.
- 2
U.S. revenue saw a significant increase of 17% in the second quarter of 2026 compared to the prior-year period.
- 3
Gross margin improved substantially to 76% in the second quarter of 2026, up from 56% in the prior-year quarter.
- 4
The company sold nine consoles in the second quarter of 2026, contributing to an expanding installed base for future circuit utilization.
- 5
First-half revenue for 2026 increased by 20% to $4.4 million compared to the prior-year period, with U.S. revenue up 24%.
- 6
Nuwellis raised approximately $12.7 million in gross proceeds through recent financing and warrant exercises, strengthening its cash position.
- 7
The company advanced its Aquadex label expansion to include patients weighing 5 kilograms or more.
Management Comments
Mike McCormick
Nuwellis has an established commercial foundation with differentiated strength in pediatrics and momentum in critical care. Our straightforward objective is to grow recurring revenue, improve operating leverage, and position Nuwellis as the leading precision fluid management company across the cardiorenal continuum. The recent infusion of capital strengthens our balance sheet and extends our cash runway, which provides financial flexibility to execute on our strategic priorities. We intend to concentrate our investments where we have clear clinical differentiation, attractive commercial opportunities, and the ability to generate sustainable shareholder value. As part of our strategic plan, we are evaluating opportunities to leverage our commercial infrastructure through complementary products and collaborations that deepen relationships within our existing hospital customers.
Informational and educational content only. Not investment advice.